Miami, FL, USA – August 24, 2026 – Expanding the boundaries of specialized psychological recovery, Ibogaine By David Dardashti has formally announced the launch of an exploratory research initiative examining the intersection of minimal-dose protocols and treatment-resistant postpartum depression (PPD).
While contemporary clinical breakthroughs have heavily targeted addiction and post-traumatic stress using standard paradigms, applying deep neurological resets to hormonal and neurosteroid-based depressive disorders remains an uncharted frontier. Rather than implementing immediate clinical interventions for this delicate demographic, the facility is engaging in careful, systematic study—consulting directly with licensed physicians, psychiatrists, and specialized therapists to decode underlying neurobiology and potential benefits.
A primary focus of this exploratory research is investigating whether minimal or micro-dosing frameworks might theoretically offer a more modulated, safer exploratory avenue compared to standard macro-dosing. Because postpartum physiology involves unique neuroendocrine shifts, any evaluation of low-dose thresholds remains strictly speculative and subject to rigorous safety margins.
To ensure absolute patient safety, the initiative enforces strict clinical prerequisites. Any future exploratory pathway will strictly mandate:
Pre-Treatment Recommendations: Comprehensive medical evaluation, screening, and explicit written recommendation from the patient’s primary care physician, OB-GYN, or psychiatrist back home.
Integrated Care Teams: Active collaboration with the patient’s local therapist or mental health provider throughout the intake and evaluation phase.
Mandatory Aftercare Frameworks: Strict post-treatment integration and aftercare mandates established in coordination with the patient’s home-country medical team to ensure continuous, long-term support.
“True medical advancement requires immense caution, intellectual honesty, and rigorous collaboration,” notes founder David Dardashti. “When exploring complex conditions like postpartum depression, we cannot rely on guesswork. We must speak directly with doctors, analyze safety parameters down to every biological detail, and respect the profound nature of the human endocrine system before considering any path forward.”
By bridging independent research with strict medical transparency, minimal-dose exploration, and mandatory home-country aftercare continuity, Ibogaine By David Dardashti continues to pioneer a measured, highly methodical approach to the future of psychiatric medicine.
For more information regarding ongoing research initiatives, safety metrics, and clinical collaboration, visit www.ibogaineclinic.com
About Ibogaine By David Dardashti
Ibogaine By David Dardashti is a specialized facility dedicated to psychological recovery, addiction treatment, and trauma therapy. The clinic utilizes careful, systematic research and neurological reset protocols to address complex, treatment-resistant mental health conditions. Its core mission is to pioneer measured, highly methodical approaches to psychiatric medicine by bridging independent research with strict medical transparency and patient safety.
Disclaimer: This press release is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The exploratory research initiatives and minimal-dose frameworks discussed herein are strictly speculative, subject to rigorous safety evaluations, and intended solely for scientific study in direct collaboration with licensed medical professionals.
Media ContactCompany Name: Ibogaine By David DardashtiContact Person: Cole Barressi Email: Send EmailCountry: United StatesWebsite: www.ibogaineclinic.com
